CT-INTERACTIVE-BROKERS
8.12.2021 15:32:07 CET | Business Wire | Press release
Interactive Brokers Group (Nasdaq: IBKR), a global brokerage firm, today introduced IMPACT to investors worldwide. IMPACT is a patent pending mobile trading application designed to help investors easily align their portfolios with their values and help shape the future they wish to see. Expanding upon our Environmental, Social and Governance (ESG) trading initiatives, IMPACT by Interactive Brokers features a simple and intuitive app design that streamlines the sustainable investing process for any investor. Following the launch of IMPACT to U.S. investors, the global launch comes at a time when ESG considerations have become increasingly important to investors on a global scale. The Global Impact Investor Network estimates the total size of the market at USD 715 billion managed by 1,720 organizations.
“IMPACT takes the utility and values alignment offered by our Impact Dashboard and places it in the palm of the investor’s hand,” said Will Peterffy, ESG Director at Interactive Brokers. “We’re leading a new generation of investors making values-based investments by enabling them to develop their own conscious investment plan based on their personal values providing accountability and transparency.”
IMPACT allows investors to select their personal investment criteria from 13 impact values and principles: Clean Air, Pure Water, Ocean Life, Land Health, Consumer Safety, Ethical Leadership, Gender Equality, Racial Equality, LGBTQ Inclusion, Company Transparency, Sustainable Product Lifecycle, Mindful Business Models, and Fair Labor & Thriving Communities. Investors can also exclude investments based on 10 categories: animal testing, business ethics controversies, corporate political spending and lobbying, energy-intensive, fossil fuels, greenhouse emissions, hazardous waste, high water usage, tobacco, alcohol and gambling, and weapons and gun manufacturers.
Based on these selections, the app provides impact scores on existing portfolios and holdings and identifies companies that align with investors’ selected criteria. (Interactive Brokers uses ESG data provided by third-party vendors and combines it with a client’s value preferences to generate impact scores.) This, along with the ability to review financial metrics for stocks and examine companies’ impact scores, affords investors the opportunity to improve their scores through the selection of alternative companies in a simple and efficient manner.
IMPACT also includes the “Swap” feature, a unique offering that gives users the ability to swap positions in the same dollar amount from one stock to another. With one tap, investors can buy and sell stocks simultaneously based on the comparative impact scores of one company versus another. This feature is only available for U.S. stocks.
“The IMPACT ‘Swap’ function goes a step further than our competitors to allow clients to easily re-align their portfolio positions with what they care about the most, which we’re really proud of,” adds Edward Soffer, ESG Manager at Interactive Brokers. “The app is designed for modern-day investors who understand that their investments make an impact and catalyze change.”
In conjunction with the launch, Interactive Brokers has partnered with One Tree Planted on the IMPACT Plant a Forest initiative. Available to the first 30,000 customers who sign up for IMPACT, the Plant a Forest program gives investors the opportunity to make an important environmental impact. For every $1,000 dollars an investor deposits in their account, IMPACT will plant 25 trees. For the equivalent of 1 tree per $40 deposited, IBKR customers who use the IMPACT app can easily help reforestation efforts and direct IMPACT to plant trees in environmentally critical regions such as California, Mexico, Côte D’Ivoire or India. One Tree Planted is a non-profit organization that plants trees worldwide to combat climate change and deforestation and partners with carefully selected reforestation organizations in North America, Latin America, Africa, and Asia.
For more information including disclosures, and to download the IMPACT app, visit:
United Kingdom: https://impact.interactivebrokers.co.uk/
Western Europe: https://impact.interactivebrokers.ie/
Central Europe: https://impact.interactivebrokers.hu/
Australia: https://impact.interactivebrokers.com.au/
Hong Kong: https://impact.interactivebrokers.com.hk/
Singapore: https://impact.interactivebrokers.com.sg/
Canada: https://impact.interactivebrokers.ca/
Other: https://impact.interactivebrokers.com
IMPACT is not available for residents of India or Japan.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 135 markets in numerous countries and currencies, from a single IBKR Integrated Investment Account to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its February 26, 2021, Best Online Broker Review.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005630/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
